

PRESS RELEASE

Of interest to editors and journalists covering:
Medical/Hospitals, Medical Research, Biotech, Education, GA News

Health Discovery Corporation announces Agreement with Stanford University for Biomarker and Pathway Discovery in Lymphatic Insufficiency.

SAVANNAH, GA - March 22, 2004 /Send2Press Newswire/ -- Health Discovery Corporation (OTC Bulletin Board: HDVY) today announced the signing of an Agreement with Stanford University to use Health Discovery Corporations proprietary and patent protected Fractal Genomics Modeling (FGM) techniques to identify new patterns of biomarkers in lymphatic insufficiency and its response to therapeutic lymphangiogenesis. According to the Agreement, ownership of Research Program Inventions conceived, discovered or reduced to practice under the Research Program will be determined based on inventorship. As such, any invention discovered using our analytical tools on this Stanford database will be jointly owned by Health Discovery Corporation and Stanford.

Stephen D. Barnhill, M.D., Chairman and Chief Executive Officer of Health Discovery Corporation stated, "It is an honor that Stanford will be working with our Company to utilize our unique approach to systems biology to discover new patterns of biomarkers and pathways associated with lymphatic insufficiency."

According to the World Health Organization, lymphedema affects 250 million people worldwide. Others estimate that one in every twenty-five will suffer from some form of lymphedema during their lifetime. The M.D. Anderson Cancer Center in Houston, Texas reports that approximately 15% of all women with breast cancer will develop lymphedema over the course of their lifetime and that lymphedema resulting from prostate cancer is on the rise.

Health Discovery Corporation is a systems biology oriented biomarker and pathway discovery company, which uses proprietary advanced mathematical platforms, such as Fractal Genomics Modeling (FGM) techniques, to help identify and characterize diagnostic targets and therapeutic candidates. Focusing on disease vs. normal, within complex genomic, proteomic and clinical data sets, Health Discovery Corporation was established to provide pharmaceutical and diagnostic companies with a broad range of analytical and decision support solutions to accelerate effective diagnostic and drug discovery. Founded in September 2003, the Company has offices in Texas, Georgia, and California. For more information contact Robert S. Braswell IV of Health Discovery Corporation +1-866-953-9031.

This news release contains "forward-looking statements" within the meaning of Section 27a of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.

More information: <http://www.healthdiscoverycorp.com>

MEDIA CONTACT:
Robert S. Braswell IV
of Health Discovery Corporation
+1-866-953-9031
info@healthdiscoverycorp.com

(OTC Bulletin Board: HDVY)

#

[source of news = Health Discovery Corporation]

ref: http://www.send2press.com/2archive/2004/pr_04_0322-hdvy.txt
http://www.send2press.com/2archivePDF/pr_04_0322-hdvy.pdf

*IMPORTANT NOTE TO MEDIA:

to reach the organization releasing this news, please contact:
info@healthdiscoverycorp.com (media only)

If used for publication, please send specimen copy.

S2PRN-R/4c/ GA / SAVANNAH, Georgia / Copr. (c) 2004 Send2Press.

This release was issued on behalf of the above organization,
who is solely responsible for accuracy of content,
by Send2Press(tm), a unit of Neotrope(R). <http://www.Send2Press.com>